Cutting edge: Importance of IL-6 and cooperation between innate and adaptive immune receptors in cellular vaccination with B lymphocytes

Journal of Immunology

Volumn 183, Issue 8, 2009, Pages 4833-4837

  Vanden Bush, Tony J ^a,c   Buchta, Claire M ^a   Claudio, Jennifer ^a,d   Bishop, Gail A ^a,b,c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Pontifical Catholic University of Puerto Rico   (Puerto Rico)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD8 ANTIGEN; INTERLEUKIN 6; RESIQUIMOD; TOLL LIKE RECEPTOR 7;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL STIMULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; IMMUNOTHERAPY; INNATE IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

ANIMALS; B-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; INTERLEUKIN-6; LISTERIA MONOCYTOGENES; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; OVALBUMIN; RECEPTORS, ANTIGEN, B-CELL; TOLL-LIKE RECEPTOR 7; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION; VACCINES;

EID: 77950841876     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0900968     Document Type: Article

References (24)

1. Freeman, G., J. Gribben, V. Boussiotis, J. Ng, V. Restivo, Jr., L. Lombard, G. Gray, and L. Nadler. 1993. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 262: 909-911. (Pubitemid 24014081)
2. Boussiotis, V., G. Freeman, G. Gray, J. Gribben, and L. Nadler. 1993. B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance. J. Exp. Med. 178: 1753-1763.
3. Freeman, G., G. Gray, C. Gimmi, D. Lombard, L. Zhou, M. White, J. Fingeroth, J. Gribben, and L. Nadler. 1991. Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J. Exp. Med. 174: 625-631.
4. + T cell priming in vivo. J. Immunol. 162: 5695-5703.
5. Lapointe, R., A. Bellemare-Pelletier, F. Housseau, J. Thibodeau, and P. Hwu. 2003. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res. 63: 2836-2843. (Pubitemid 36667155)
6. Schultze, J., S. Michalak, M. Seamon, G. Dranoff, K. Jung, J. Daley, J. Delgado, J. Gribben, and L. Nadler. 1997. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J. Clin. Invest. 100: 2757-2765.
7. Schultze, J., S. Grabbe, and M. von Bergwelt-Baildon. 2004. DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy. Trends Immunol. 25: 659-664.
8. Vanden Bush, T., and G. Bishop. 2008. TLR7 and CD40 cooperate in IL-6 production via enhanced JNK and AP-1 activation. Eur. J. Immunol. 38: 400-409.
9. Baccam, M., S. Woo, C. Vinson, and G. Bishop. 2003. CD40-mediated transcriptional regulation of the IL-6 gene in B lymphocytes: involvement of NF-κB, AP-1, and C/EBP. J. Immunol. 170: 3099-3108.
10. Bishop, G., L. Ramirez, M. Baccam, L. Busch, L. Pederson, and M. Tomai. 2001. The immune response modifier resiquimod mimics CD40-induced B cell activation. Cell. Immunol. 208: 9-17.
11. Bishop, G., Y. Hsing, B. Hostager, S. Jalukar, L. Ramirez, and M. Tomai. 2000. Molecular mechanisms of B lymphocyte activation by the immune response modifier R-848. J. Immunol. 165: 5552-5557.
12. Vasilakos, J., R. Smith, S. Gibson, J. Lindh, L. Pederson, M. Reiter, M. Smith, and M. Tomai. 2000. Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cell. Immunol. 204: 64-74.
13. Weeratna, R., S. Makinen, M. McCluskie, and H. Davis. 2005. TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). Vaccine 23: 5263-5270.
14. Haxhinasto, S., and G. Bishop. 2004. Synergistic B cell activation by CD40 and the B cell antigen receptor: role of B lymphocyte antigen receptor-mediated kinase activation and tumor necrosis factor receptor-associated factor regulation. J. Biol. Chem. 279: 2575-2582.
15. Bishop, G., L. Ramirez, and T. Waldschmidt. 1994. Differential responses to Ig and class II-mediated signals in splenic B cell subsets from normal and autoimmune mice. Int. Immunol. 6: 1049-1059. (Pubitemid 24221416)
16. Pope, C., S. Kim, A. Marzo, D. Masopust, K. Williams, J. Jiang, H. Shen, and L. Lefrancois. 2001. Organ-specific regulation of the CD8 T cell response to Listeria monocytogenes infection. J. Immunol. 166: 3402-3409.
17. Kraus, Z., J. Haring, and G. Bishop. 2008. TNF receptor-associated factor 5 is required for optimal T cell expansion and survival in response to infection. J. Immunol. 181: 7800-7809.
18. Shen, S., Z. Xu, X. Qian, Y. Ding, L. Yu, and B. Liu. 2008. RNA-electroporated CD40-activated B cells induce functional T-cell responses against HepG2 cells. Eur. J. Cancer Care (Engl.) 17: 404-411.
19. Sepulveda, H., A. Cerwenka, T. Morgan, and R. Dutton. 1999. CD28, IL-2-independent costimulatory pathways for CD8 T lymphocyte activation. J. Immunol. 163: 1133-1142. (Pubitemid 29352727)
20. Nikbin, B., M. Bonab, F. Khosravi, and F. Talebian. 2007. Role of B cells in pathogenesis of multiple sclerosis. Int. Rev. Neurobiol. 79: 13-42.
21. Racke, M. 2008. The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies. Curr. Opin. Neurol. 21(Suppl. 1): S9-S18.
22. Schlaepfer, E., A. Audige, H. Joller, and R. Speck. 2006. TLR7/8 triggering exerts opposing effects in acute versus latent HIV infection. J. Immunol. 176: 2888-2895. (Pubitemid 43306949)
23. Morales-Aza, B., S. Glennie, T. Pereira Garcez, V. Davenport, S. L. Johnston, N. Williams, and R. Heyderman. 2009. Impaired maintenance of naturally acquired T cell memory to the meningococcus in individuals with B cell immunodeficiency. Blood 4206-4212.
24. Nencioni, A., F. Grunebach, S. Schmidt, M. Muller, D. Boy, F. Patrone, A. Ballestrero, and P. Brossart. 2008. The use of dendritic cells in cancer immunotherapy. Crit. Rev. Oncol. Hematol. 65: 191-199. (Pubitemid 351200461)